Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Atomoxetine recalled?

Yes — there is an active recall. 15 ongoing FDA recalls mention Atomoxetine (19 total). Check the affected lots below.

Most common reason: Nitrosamine impurity (14 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Atomoxetine. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Atomoxetine recalls in 2026

1 initiated in 2026, 19 in total — newest first
Class II · Moderate risk

Atomoxetine Capsules HCL

Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.

Ongoing Labeling / mix-up Safecor Health, LLC D-0538-2026
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-761-01 D-0244-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-760-01 D-0243-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-759-01 D-0242-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-758-01 D-0241-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-757-01 D-0240-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-756-01 D-0239-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-755-01 D-0238-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-271-30 D-0237-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-270-30 D-0236-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-269-30 D-0235-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-268-30 D-0234-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-267-30 D-0233-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-266-30 D-0232-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-265-30 D-0231-2025
Class II · Moderate risk

Atomoxetine HCl active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-527-2015
Class II · Moderate risk

Atomoxetine HCL

Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 80 mg may be potentially mis-labeled as one of the following drugs: ATOMOXETINE HCL, Capsule, 18 mg, NDC 00002323830, Pedigree: AD30140_16, EXP: 5/7/2014; PRENATAL MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, NDC 00904531360, Pedigree: W003706, EXP: 6/25/2014; RANOLAZINE ER, Tablet, 500 mg, NDC 61958100301, Pedigree: AD60272_40, EXP: 5/22/2014; PRO

Terminated Labeling / mix-up Aidapak Services, LLC D-768-2014
Class II · Moderate risk

Atomoxetine HCL

Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 18 mg, may be potentially mis-labeled as the following drug: LOVASTATIN, Tablet, 20 mg, NDC 00185007201, Pedigree: AD28369_1, EXP: 5/7/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-767-2014
Class II · Moderate risk

Atomoxetine HCL

Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 40 mg may be potentially mis-labeled as OLANZAPINE, Tablet, 7.5 mg, NDC 60505311203, Pedigree: AD21790_76, EXP: 5/1/2014; ARIPiprazole, Tablet, 2 mg, NDC 59148000613, Pedigree: AD46265_19, EXP: 5/15/2014; OLANZapine, Tablet, 7.5 mg, NDC 55111016530, Pedigree: AD60272_79, EXP: 5/22/2014; OLANZapine, Tablet, 7.5 mg, NDC 55111016530, Pedigree: AD73

Terminated Labeling / mix-up Aidapak Services, LLC D-765-2014